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Abstract
Background: Non-motor symptoms (e.g., depression, anxiety, and cognitive deficits) in patients with Parkinson disease (PD)
precede the onset of the motor symptoms. Although these symptoms do not respond to pharmacological dopamine
replacement therapy, their precise pathological mechanisms are currently unclear. The present study was undertaken to
examine whether the unilateral 6-hydroxydopamine (6-OHDA) lesion to the substantia nigra pars compacta (SNc), which
represents a model of long-term dopaminergic neurotoxicity, could affect cell proliferation in the adult rat brain.
Furthermore, we examined the effects of the selective serotonin reuptake inhibitor (SSRI) fluoxetine and the selective
noradrenaline reuptake inhibitor maprotiline on the reduction in cell proliferation in the subgranular zone (SGZ) by the
unilateral 6-OHDA lesion.
Methodology/Principal Findings: A single unilateral injection of 6-OHDA into the rat SNc resulted in an almost complete
loss of tyrosine hydroxylase (TH) immunoreactivity in the striatum and SNc, as well as in reductions of TH-positive cells and
fibers in the ventral tegmental area (VTA). On the other hand, an injection of vehicle alone showed no overt change in TH
immunoreactivity. A unilateral 6-OHDA lesion to SNc significantly decreased cell proliferation in the SGZ ipsilateral to the 6-
OHDA lesion, but not in the contralateral SGZ or the subventricular zone (SVZ), of rats. Furthermore, subchronic (14 days)
administration of fluoxetine (5 mg/kg/day), but not maprotiline significantly attenuated the reduction in cell proliferation in
the SGZ by unilateral 6-OHDA lesion.
Conclusions/Significance: The present study suggests that cell proliferation in the SGZ of the dentate gyrus might be, in
part, under dopaminergic control by SNc and VTA, and that subchronic administration of fluoxetine reversed the reduction
in cell proliferation in the SGZ by 6-OHDA. Therefore, SSRIs such as fluoxetine might be potential therapeutic drugs for non-
motor symptoms as well as motor symptoms in patients with PD, which might be associated with the reduction in cell
proliferation in the SGZ.
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Introduction
Parkinson’s disease (PD) is a chronic and progressive neurode-
generative disease with multiple motor and non-motor features
that contribute to the impairment of health-related quality of
life (QOL). The pathologic hallmark of PD is degeneration of
dopaminergic neurons in the substantia nigra pars compacta
(SNc), resulting in depletion of striatal dopamine, which regulates
excitatory and inhibitory outflow of the basal ganglia [1–3]. With
improvements in the treatment of motor symptoms, PD’s non-
motor symptoms (e.g., depression, anxiety, cognitive deficits, and
olfactory dysfunction) have been increasingly recognized as a
major cause of disability, particularly neuropsychiatric features
(e.g., depression and anxiety) and cognitive impairments [4–11].
Depression occurs in approximately 45% of patients with PD and
does not correlate with the stage of motor deficits; moreover, it
reduces QOL independently of motor symptoms and it appears to
be underrated and undertreated [11,12]. In addition, non-motor
symptoms, including depression and anxiety, occur not only after
the onset of motor symptoms but also may develop many years,
even decades, before the onset of PD, suggesting these neuropsy-
chiatric symptoms are risk factors for the development of PD
[11–13]. Collectively, these data suggest the need for earlier
evaluation and treatment of non-motor symptoms (e.g., depres-
sion, anxiety, and cognitive deficits) in PD, which potentially could
improve health-related QOL and patient productivity while
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reducing morbidity and minimizing direct and indirect healthcare
costs [11].
Several lines of evidence suggest that serotonergic, noradrener-
gic, and dopaminergic mechanisms play key roles in the etiology of
non-motor symptoms such as depression in PD. Antidepressants
such as selective serotonin reuptake inhibitors (SSRIs) appear to
be effective in treating depression in PD [11,14–18]. The anti-
cholinergic effects of tricyclic antidepressants are especially
problematic in patients with PD, since they may also worsen
cognition or aggravate orthostatic hypotension. Thus, it appears
that SSRIs are generally well tolerated in patients with PD [11,16].
Accumulating evidence suggests that the induction of neuro-
genesis in the hippocampus may be involved in the mechanisms of
action of antidepressants such as SSRIs as well as in cognitive
functions such as learning and memory [19–25]. Additionally,
dopamine is also shown to play a role in the regulation of neural
progenitor cells, because the depletion of dopamine in animal
models of PD decreased the numbers of neural progenitor cells
in the neurogenic regions of the brain [26–30]. Interestingly,
Ho¨glinger et al. [28] reported that the numbers of proliferating
cells in the subependymal zone and neural precursor cells in the
subgranular zone (SGZ) and olfactory bulb are reduced in
the postmortem brains of patients with PD, suggesting that the
generation of neural precursor cells is impaired in PD as a
consequence of dopaminergic denervation. Taken together, the
results suggest it is likely that reduced neurogenesis might be
involved in the non-motor symptoms as well as motor symptoms
in patients with PD. It is therefore suggested that increasing
endogenous neurogenesis could provide a novel treatment
paradigm for both motor and non-motor symptoms in patients
with PD.
The present study was undertaken to examine whether the 6-
hydroxydopamine (6-OHDA)-induced unilateral lesion to the
SNc, which represents a model of long-term dopaminergic
neurotoxicity, could affect the number of proliferating cells in
the SGZ of the dentate gyrus in the adult rat brain (Fig. 1).
Furthermore, we examined the effects of the most widely
prescribed SSRI, fluoxetine and the selective norepinephrine
reuptake inhibitor maprotiline, on the reduction in the number of
proliferating cells in the SGZ by the unilateral 6-OHDA lesion
(Fig. 1).
Results
The extent of dopaminergic lesioning was determined from a
series of coronal sections stained for tyrosine hydroxylase (TH)
immunohistochemistry (Fig. 2). A single unilateral injection of
6-OHDA into the midbrain resulted in an almost complete loss of
TH immunoreactivity in the striatum (Fig. 2B) and SNc (Fig. 2D,
F), and in reductions in the number of TH-positive cells and fibers
in the ventral tegmental area (VTA) (Fig. 2H), while an injection
of vehicle alone showed no overt change in TH immunoreactivity
(Fig. 2A, C, E and G). In the 6-OHDA group, TH-positive fibers
in the hilus and granular cell layer of the dentate gyrus in the right
hippocampus, ipsilateral to the lesioning, completely disappeared
(Fig. 2J, L), unlike the case with that in the contralateral
hippocampus (Fig. 2I, K).
Using BrdU immunohistochemistry, we examined the effect of
the loss of dopaminergic projection on cell proliferation in the
SVZ of the lateral ventricle and the SGZ of the dentate gyrus of
the hippocampus. Results from a representative animal which had
been lesioned by 6-OHDA and treated by subchronic saline were
shown in Fig. 3. In the SVZ, BrdU-positive cells were distributed
singly or in nested clusters throughout the SVZ (Fig. 3A, B).
Stereological quantification revealed that the numbers of BrdU-
positive cells in the SVZ were similar in both hemispheres (data
not shown). In the hippocampus, BrdU-positive cells were sparsely
distributed in the SGZ (Fig. 3C, D). 6-OHDA-induced
dopaminergic denervation significantly decreased the number of
BrdU-positive cells in the SGZ ipsilateral to the lesion (Fig. 3D).
We then examined the effect of subchronic treatment with
fluoxetine in doses of 0 (saline), 1.25, 2.5 or 5 mg/kg/day for 14
days on the cell proliferation in the SGZ associated with a loss of
dopaminergic projections. Stereological analysis in 6-OHDA-
lesioned animals with saline treatment revealed fewer BrdU-
positive cells in the ipsilateral SGZ than in the contralateral SGZ,
and that there was no such decrease in 6-OHDA-lesioned animals
treated by 5 mg/kg of fluoxetine (Fig. 4). Two-way ANOVA
showed no significant interaction between Treatment and Side
(F5,78 = 2.16, p = 0.07). One-way ANOVA revealed that the
numbers of BrdU-positive cells differed significantly among groups
on the ipsilateral side (F5,44 = 6.85, p,0.001) but not on the
contralateral side (F5,44 = 0.45, p = 0.81). A post hoc Bonferroni test
revealed significantly fewer BrdU-positive cells in the SGZ
ipsilateral to the 6-OHDA lesioning in 6-OHDA group animals
that received saline or 1.25 mg/kg of fluoxetine treatment than
that in other conditions (p,0.01 each). BrdU-positive cells in
animals treated with 10 mg/kg of maprotiline, a selective
noradrenaline reuptake inhibitor, were also reduced in the
ipsilateral to the 6-OHDA lesioning. This is the first report of a
beneficial effect of an SSRI on the reduction in cell proliferation
induced by dopaminergic lesioning of the midbrain in the adult
rodent hippocampus.
We further examined the effect of fluoxetine treatment on the
spatial learning task in animals with 6-OHDA lesioning. In the
Morris water maze task, the escape latency to the platform
in animals, which had been treated wither with saline or with
fluoxetine, decreased significantly as the training progressed
(repeated measure one-way ANOVA with Dunnett’s multiple
Figure 1. Experimental paradigms. (A) Proliferation paradigm.
Animals received intra-SNc injection of 6-OHDA or vehicle. Seven days
after the surgery, animals were injected with fluoxetine, maprotiline, or
saline for 14 days. A day after the last injection, animals were given
BrdU and sacrificed. (B) Differentiation paradigm. Animals were given
intra-SNc injection of 6-OHDA. Seven days after the surgery, animals
were injected with fluoxetine or saline for 14 days and given BrdU.
Twenty-four days after the injection of BrdU, animals were given Morris
water maze (MWM) tasks for 3 days, and then sacrificed.
doi:10.1371/journal.pone.0009260.g001
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comparison, F5,20 = 11.5, p,0.01 for fluoxetine; F5,20 = 27.1,
p,0.01 for saline), suggesting that the animals could learn the
task irrespective of the drug treatment (Fig. 5).
To detect the differentiation of surviving BrdU positive cells in
animals with 6-OHDA lesioning, we used NeuN as a mature
neuronal marker and GFAP as a marker for astrocytes, as shown
in Fig. 6. Four weeks of fluoxetine treatment after the BrdU
injection, the number of BrdU-positive cells in the dentate
granular cell layer was 30.563.1 (mean 6 S.E.M.) cells/mm2
and 18.463.2 cells/mm2 in rats treated either with subchronic
fluoxetine or with saline, respectively. The difference was
statistically significant as assessed by unpaired t test (t8 = 2.71,
p = .027). We observed that most of BrdU-positive cells were
immunoreactive to NeuN (mean 6 S.E.M., 83.163.5%, Fig. 6A),
whereas few BrdU-positive cells were immunoreactive to GFAP
(13.962.5%, Fig. 6B) in fluoxetine treated animals.
Discussion
The major findings of the present study are that a unilateral 6-
OHDA lesion to the SNc in rat significantly decreased cell
proliferation in the SGZ ipsilateral to the lesion, but not in the
contralateral SGZ or SVZ, and that subchronic (14 days)
administration of fluoxetine, but not maprotiline, significantly
attenuated the reduction in cell proliferation in the SGZ by
unilateral 6-OHDA lesion. This is a first report to demonstrate that
a unilateral 6-OHDA lesion to SNc caused a reduction of cell
proliferation in the SGZ ipsilateral, but not contralateral, to the
lesion. These findings suggest that cell proliferation in the SGZmight
be, in part, under dopaminergic control from SNc and VTA since
the hippocampus receives dopaminergic input from both [31–33].
Accumulating evidence suggests that dopamine is a potent
stimulator of endogenous neural precursor cell proliferation in the
SVZ and SGZ in the adult brain [26–30,34]. Ho¨glinger et al. [28]
Figure 2. Reduced TH immunoreactivity in the striatum,
midbrain, and hippocampus following 6-OHDA lesioning. (A,
B) Coronal sections of the striatum immunostained for TH in
representative animals from the sham group (A) and 6-OHDA group
(B). Almost complete loss of TH immunoreactivity is observed in the
right striatum (dotted area) of the 6-OHDA group animal. (C, D) Coronal
sections of the midbrain immunostained for TH in animals from the
sham group (C) and 6-OHDA group (D). (E–H) Sections of the SNc (E, F)
and ventral tegmental area (G, H) at higher magnification of C and D. is
The 6-OHDA group animal (F, H) has fewer TH-positive dopaminergic
cells than the sham-operated animal (E, G). (I–L) Coronal sections of the
hippocampus in animals from the sham group (I, K) and 6-OHDA group
(J, L). TH-positive fibers are observed in the hilus (h) as well as in the
granular cell layer (g) of the dentate gyrus in the sham group animal
(I, K), which is completely lost in the 6-OHDA lesioned animal (J, L).
doi:10.1371/journal.pone.0009260.g002
Figure 3. Cell proliferation in the SVZ and SGZ. (A, B) Coronal
sections of the SVZ of the lateral ventricle contralateral (A) or ipsilateral
(B) to the 6-OHDA lesioning in an animal from the 6-OHDA group. BrdU-
positive nuclei are clearly observed. (C, D) Sections of the dentate gyrus
of the hippocampus contralateral (C) or ipsilateral (D) to the 6-OHDA
lesioning. BrdU-positive cells (arrows) are observed in the SGZ of the
dentate gyrus.
doi:10.1371/journal.pone.0009260.g003
Figure 4. Cell proliferation in the SGZ after antidepressant
treatment. Reduction of cell proliferation in animals given 6-OHDA
lesioning was rescued by 2 weeks of treatment with fluoxetine (5 mg/
kg) to a level comparable to that of contralateral side. *Significantly
lower than the corresponding value in the contralateral side.
{Significantly higher than corresponding values of 6-OHDA group
animals treated with saline.
doi:10.1371/journal.pone.0009260.g004
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reported the effect of dopaminergic denervation on cell prolifer-
ation in the SVZ and SGZ in the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-treated mice, an animal model
of PD. MPTP (four injections of 10 mg/kg at 2-hour intervals)
induced a complete loss of dopaminergic fibers in the SNc that
fully recovered within 70 days. Cell proliferation in the SGZ first
decreased and then recovered in parallel with dopaminergic
denervation and reinnervation, respectively [28]. There is also a
close anatomical relationship between afferent dopaminergic fibers
and proliferating cells to be preserved in the SVZ of non-human
primates [27]. Interestingly, the reduction in the number of
proliferating precursor cells in the SVZ and SGZ of postmortem
brain tissue from patients with PD was reported [28]. Further-
more, Hiramoto et al. [35] reported that dopamine receptor
agonist apomorphine increased the number of BrdU-positive cells
in SGZ, and that dopamine D2 receptor antagonist blocked the
increase in BrdU-positive cells by apomorphine, suggesting that
the stimulation of dopamine D2 receptors can increase cell
proliferation in the SGZ. Taken together, the results suggest it is
likely that cell proliferation in the SGZ of the dentate gyrus might
be under dopaminergic control.
Freundlieb et al. [27] reported the existence of a topographically
organized dopaminergic projection from the SNc to the SVZ in
aged primates. MPTP treatment (four to six MPTP injections per
animal; cumulative dose, 1.2–2.0 mg/kg) caused a significant
decrease in the number of proliferating cells in the denervated
regions of the SVZ, suggesting that an intact dopaminergic nigro-
subventricular innervation is crucial for sustained neurogenesis in
aged primates [27]. However, in the present study we found no
alteration in the number of proliferating cells in the SVZ of adult
rat brain after ipsilateral 6-OHDA lesioning. The precise reasons
underlying the difference between the two studies are currently
unknown. One possibility may be the differences in the
degenerative profile (systemic MPTP injection (complete lesion
model) vs. ipsilateral 6-OHDA lesion (partial lesion model)).
Another possibility is that the intact dopaminergic neurons on the
contralateral side may compensate for dopaminergic transmission
to SVZ, although further study is necessary.
As mentioned, we observed that subchronic (14 days) admin-
istration of fluoxetine (5 mg/kg/day) significantly attenuated the
reduction in cell proliferation in the SGZ ipsilateral to the
6-OHDA lesion, but not in the contralateral SGZ or in control
rats. To the best of our knowledge, this is the first report of a
beneficial effect of an SSRI on the reduction in cell proliferation
induced by dopaminergic lesioning of the midbrain in the adult
rodent hippocampus. Malberg and Duman [36] reported that cell
proliferation in the adult hippocampus is decreased by inescapable
stress, and that fluoxetine treatment (10 mg/kg b.i.d. for 7 days)
blocked the downregulation of cell proliferation resulting from
inescapable stress. Furthermore, repeated treatment with fluoxe-
tine (10 mg/kg/day for 10 days) could reverse the reduction in the
number of proliferating cells in the SGZ of streptozotocin (STZ)-
induced diabetic mice, but not control mice [37]. Thus, it should
be noted that fluoxetine can reverse the reduction in cell
proliferation in the SGZ by 6-OHDA lesion, stress, or STZ. In
contrast, some other reports showed that chronic administration of
fluoxetine increased the number of cell proliferation in the SGZ of
control rats [38–42], which is inconsistent with the present results.
Figure 5. Mean escape latency in the Morris water maze task.
There was no significant difference between the treatments.
doi:10.1371/journal.pone.0009260.g005
Figure 6. Differentiation of BrdU-positive cells in the dentate
gyrus in rats 28 days after the subchronic treatment with
fluoxetine. BrdU-positive cells (green) were co-labeled with a neuronal
marker, NeuN (A), but not GFAP (B). Scale bars: 400 mm in lower
magnification and 40 mm in higher magnification.
doi:10.1371/journal.pone.0009260.g006
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It seems that treatment schedule (e.g., dose, treatment interval)
may contribute to this discrepancy, although the precise reasons
underlying the discrepancy are currently unclear.
In this study, we found that, in Morris water maze task,
6-OHDA lesioning did not develop non-motor symptoms (e.g.,
learning and memory), suggesting that unilateral reduction in the
hippocampal neurogenesis by the hemispheric dopaminergic
deprivation may not be sufficient to develop behavioral non-
motor symptoms (e.g., cognitive deficits). The aforementioned
findings suggest that the reduction of cell proliferation in the SGZ
of the adult hippocampus may be involved in the non-motor
symptoms (e.g., depression, anxiety, and cognitive deficits) as well
as in the motor symptoms in patients with PD. Considering the
beneficial effects of SSRIs (e.g., fluoxetine) in the regulation of cell
proliferation in the SGZ, it seems that SSRIs such as fluoxetine
would be potential therapeutic drugs for PD. Some papers have
demonstrated that antidepressants such as SSRIs are effective in
the treatment of depression in patients with PD [14–18]. Non-
motor symptoms may develop many years, even decades, before
the onset of PD [11–13], suggesting these neuropsychiatric
symptoms are risk factors for the development of PD. Taken all
together, the past and present results indicate that SSRIs such as
fluoxetine may delay or prevent the onset of PD in patients with
prodromal non-motor symptoms. A randomized, double-blind,
placebo-controlled study of SSRIs in the prodromal non-motor
symptoms of PD is needed to confirm our hypothesis.
It is known that noradrenergic innervation that originates in the
locus coeruleus terminates diffusely throughout the hippocampus,
and one of subregions where the highest density occurs is the just
inferior to the granular cell layer of dentate gyrus. Since anti-TH
immunohistochemistry recognizes noradrenergic fibers, the reduc-
tion in TH immunoreactivity in the hilus of 6-OHDA treated rats
(Fig. 2L) indicates that noradrenergic as well as dopaminergic
inputs to the hippocampus have been affected by 6-OHDA
treatment in our study. Axons of the locus coeruleus project to
the hippocampus via the dorsal bundle, which ascends to traverse
the midbrain tegmentum [43]. Due to our coordinate for the
stereotaxic injection, which had intended to avoid the hippocampal
injury, 6-OHDA solution along the needle track might have affected
noradrenergic axons in the vicinity of the injection site. Therefore,
the finding suggests that decrease in hippocampal neurogenesis
might be a result from not only dopaminergic destruction but also
reduction of noradrenergic inputs to the hippocampus by intra-SNc
6-OHDA. From the clinical viewpoint, the locus coeruleus appears
to be constantly affected in PD, as witnessed by the extensive cell loss
occurring PD patients [44–46]. Noradrenaline levels in several
brain regions of PD patients have been shown to be significantly
reduced [47]. Therefore, the ameliorating effect of SSRI on the
decrease in hippocampal neurogenesis after 6-OHDA treatment
implies that SSRI would be beneficial for PD patients who have
deficiency in both dopaminergic and noradrenergic systems.
In conclusion, the present study suggests that cell proliferation
in the SGZ of the dentate gyrus of the adult rat brain might be
under dopaminergic control from SNc and VTA. Additionally,
SSRIs such as fluoxetine potentially are therapeutic drugs for non-
motor symptoms as well as motor symptoms in patients with PD,
since fluoxetine can reverse the downregulation of cell prolifera-
tion in the SGZ by 6-OHDA lesion.
Materials and Methods
Animals
Adult Sprague-Dawley rats weighing 240–260 g (Japan SLC,
Hamamatsu, Japan) were used in this study. The animals were
housed in groups of three in a temperature- and humidity-
controlled room that was kept on a 12-h light/dark cycle. Food
and water were available ad libitum throughout the study. All
experiments were performed in accordance with the Guide for
Animal Experimentation at the Hamamatsu University School
of Medicine. All efforts were made to minimize the number of
animals used and their suffering. All surgeries were performed
following an intraperitoneal (IP) injection of sodium pentobarbital
at 50 mg/kg of body weight.
Surgery
After at least 7 days of habituation to the rat colony, animals
were divided into two groups: 6-OHDA (n= 56) and sham (n= 8).
Animals in the 6-OHDA group were injected stereotaxically with
6 mg of 6-hydroxydopamine (6-OHDA, Sigma-Aldrich, Tokyo,
Japan) dissolved in 2 ml of saline containing 0.02% ascorbic acid
over a 10 min period into the right substantia nigra pars compacta
(SNc) at the following coordinates: AP, 24.8 mm; ML, 1.5 mm
with respect to the bregma; and 7.8 mm below the dura. Sham
group animals were injected with the same volume of vehicle into
the right SNc.
Antidepressant Treatment
To test the effect of fluoxetine, an established antidepressant
SSRI, on cell proliferation in animals given 6-OHDA, 35 animals
from the 6-OHDA group and 10 animals from the sham group
were used. As of the next day to the surgery as described above,
the 6-OHDA group animals were injected intraperitoneally (IP)
either with saline (1 ml/kg, n = 10), fluoxetine (1.25 mg/kg, n= 5;
2.5 mg/kg, n = 5; or 5 mg/ml/kg, n = 10), or with maprotiline, a
selective noradrenaline reuptake inhibitor (10 mg/kg, n= 5) once
daily for 14 days. Sham group animals were given 5 mg/kg of
fluoxetine once daily for 14 days (Fig. 1A). To test the effect of
subchronic treatment with fluoxetine on cell differentiation, 10
animals from the 6-OHDA group were used. As of the next day to
the surgery, the 6-OHDA group animals were treated IP either
with saline (1 ml/kg, n = 5) or fluoxetine (5 mg/kg, n= 5) once
daily for 14 days. Animals were then allowed to survive for 28 days
(Fig. 1B).
Morris Water Maze Task
To determine if the fluoxetine treatment affects hippocampus
dependent memory function in animals given 6-OHDA, we used a
Morris water maze (MWM) task for animals in the differentiation
paradigm. The animals were given a session of the task for 3 days.
Each session consisted of six trials lasting 60 s each, separated by a
60 s inter-trial interval. At the start of each trial, rats were placed
at one of four start locations at the limb of a circular pool (150 cm
in diameter, water temperature at 26uC) with their face toward the
wall. Animals were required to escape to an invisible platform
(10 cm in diameter, 1 cm below the water surface) fixed at a
predetermined location. If animals could not reach the platform
within 60 s, an experimenter gently led them onto the platform.
Once animals got upon the platform, they were left on it for 15 s
and then returned to a waiting cage.
5-Bromo-29-Deoxyuridine (BrdU) Labeling and Tissue
Processing
Twenty-four hours after the last injection of saline, fluoxetine or
maprotiline, the animals were injected with a proliferation marker
BrdU (100 mg/kg, IP). Two hour or 28 days after the BrdU
administration, animals were deeply anesthetized with 100 mg/kg
of pentobarbital and sacrificed by transcardial perfusion with
Dopamine and Neurogenesis
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physiological saline followed by 0.1 M phosphate-buffered 4%
paraformaldehyde. The brains were removed, cryoprotected by
20% sucrose in 0.1 M phosphate buffer overnight, frozen with dry
ice, and cut into 30-mm-thick serial coronal sections by means of a
cryostat. The sections were divided into six section series (i.e., the
first series includes the 1st, 7th, 13th …, the second series includes
the 2nd, 8th, 14th…, and so on) and stored in 0.1 M phosphate-
buffered saline at 4uC until their use in histological examinations.
Histology
The first series sections through the hippocampus and midbrain
were stained with cresyl violet for Nissl staining to evaluate
injection sites. The second series sections were immunostained for
tyrosine hydroxylase (TH) in order to label soma and fibers of
dopaminergic neurons. Sections were serially incubated with anti-
TH polyclonal antibody (1:300; Sigma-Aldrich Japan Inc., Tokyo,
Japan) and biotinylated horse-anti-rabbit IgG (1:500; Vector
Laboratories, Burlingame, CA, USA). The third series sections
were stained with mouse monoclonal anti-BrdU antibody
(0.6 mg/mL; Becton Dickinson Immunocytometry Systems, San
Jose, CA, USA) and biotinylated horse-anti-mouse IgG (1:160;
Vector Laboratories) to visualize proliferating cells. Immunoreac-
tive signals were visualized using an ABC kit (Vector Laboratories)
and 3,39-diaminobenzidine (Sigma-Aldrich Japan, Tokyo, Japan).
Immunofluorescence
The phenotype of newborn cells was examined with double-
labeled immunofluorescence. The sections were denatured,
washed, and incubated with the rat monoclonal anti-BrdU
antibody (0.6 mg/mL; Becton Dickinson Immunocytometry
Systems, San Jose, CA, USA) and subsequently with either a
mouse monoclonal anti-neuronal nuclei (NeuN) antibody (1:1000,
Chemicon, Temecula, CA, USA) or a rabbit polyclonal anti-glial
fibrillary acidic protein (GFAP) antibody (1:2000, DAKO,
Copenhagen-Glostrup, Denmark) at 4uC overnight. Then sections
were incubated with Alexa 488 donkey anti-rat IgG (1:1000,
Molecular Probes) and with Alexa Fluor 546 goat anti-mouse IgG
(1:1000, Molecular Probes) or Alexa Fluor 546 goat anti-rabbit
IgG (1:2000, Molecular Probes) for 1 h at room temperature.
Fluorescent signals were detected using a fluorescent microscope
(BioZero8000, Keyence Corp., Japan).
Cell Counts
The procedure for nonbiased stereological cell counts has been
described elsewhere [48]. Briefly, BrdU-positive proliferating cells
were counted on every 6th section throughout the rostrocaudal
extent of the brain using the StereoInvestigator system (Micro-
brightfield Japan, Chiba, Japan) and an Olympus BX40
microscope equipped with a motorized stage driven in the X, Y,
and Z planes. BrdU-positive cells in the subventricular zone (SVZ)
of the lateral ventricle and subgranular zone (SGZ) of the dentate
gyrus of the hippocampus were carried out exhaustively through
every 6th section at 406 magnification in order to estimate the
total number of cells in each structure. The volumes of the SVZ,
SGZ, dentate granular layer, and hilus were estimated according
to Cavalieri’s principle.
In the differentiation paradigm, BrdU-positive cells were
counted manually under a fluorescent microscope. At least 10
sections in the hippocampus ipsilateral to the 6-OHDA lesioning
were studied in each animal treated either with fluoxetine (n = 5)
or with saline (n = 5). The same areas and number of sections were
studied for all the animals. The granular cell layer (GCL) was
traced by using a camera lucida, and drawings were scanned and
processed with NIH Image software to determine the area of the
GCL at each level examined. The reference volume of the GCL
was determined by summing the traced areas of GCL in each
section and multiplying the result by the distance between sampled
sections (180 mm). All BrdU-labeled cells in the selected area were
counted in terms of cells/mm2.
Statistical Analysis
The main dependent variable was the number of BrdU-positive
cells. Two-way analysis of variance (ANOVA) was conducted to
test the effects of ‘Treatment’ (saline, fluoxetine, and maprotiline)
and ‘Side’ [right (ipsilateral to the lesion) and left] on the
dependent variable. When we found significant interaction
between ‘Treatment’ and ‘Side’, we subsequently repeated one-
way ANOVA for each ‘Side’ separately (i.e., right versus left) to see
whether any distinct patterns of the dependent variable among
treatments would emerge between the sides. According to the
results of one-way ANOVA, we further carried out post hoc pair
comparisons using Bonferroni’s test. All values and graphs are
shown as mean 6 standard error of the mean (SEM). All statistical
analysis was performed using statistical analysis software (SPSS
version 12.0J). The level of significance was set at p,0.05.
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